Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma

Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refract...

Full description

Bibliographic Details
Main Authors: Morel, Armand, Talbot, Denis
Format: Online
Language:English
Published: Dove Medical Press 2010
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819039/
id pubmed-3819039
recordtype oai_dc
spelling pubmed-38190392013-11-06 Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma Morel, Armand Talbot, Denis Review Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refractory disease, there is currently no standard treatment. Vinflunine, a second-generation Vinca alkaloid, is the first chemotherapeutic agent to be evaluated in a large UC second-line population. This review discusses the pre-clinical and clinical data published, and compares vinflunine to alternative single agents and combination regimens tested in this setting. Based on the results of the phase II and III clinical trials, there appears to be sufficient evidence to support the use of vinflunine in the second-line setting. Dove Medical Press 2010-06-29 /pmc/articles/PMC3819039/ /pubmed/24198619 Text en © 2010 Morel and Talbot, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Morel, Armand
Talbot, Denis
spellingShingle Morel, Armand
Talbot, Denis
Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
author_facet Morel, Armand
Talbot, Denis
author_sort Morel, Armand
title Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
title_short Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
title_full Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
title_fullStr Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
title_full_unstemmed Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
title_sort critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
description Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refractory disease, there is currently no standard treatment. Vinflunine, a second-generation Vinca alkaloid, is the first chemotherapeutic agent to be evaluated in a large UC second-line population. This review discusses the pre-clinical and clinical data published, and compares vinflunine to alternative single agents and combination regimens tested in this setting. Based on the results of the phase II and III clinical trials, there appears to be sufficient evidence to support the use of vinflunine in the second-line setting.
publisher Dove Medical Press
publishDate 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819039/
_version_ 1612023853039484928

Similar Items